Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-2021 in Recurrent Malignant Glioma
NCT06585527Phase 1Recruiting
- Sponsor
- Beijing Neurosurgical Institute
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TS-2021 in malignant glioma, sponsored by Beijing Neurosurgical Institute. Primary endpoints: Incidence and severity of adverse events at 8 weeks and Overall Survival at 12 months. Started Aug 2024; status: recruiting.
02
Drugs
TS-2021
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT06585527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585527.